TRIAL DETAIL
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Neoplasm |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 11/01/2014 |
Age of Trial (yrs) 10.4 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
BCL-2 inhibitor + KIT inhibitor |
|||
Strategy: |
Block KIT + Unblock cell death genes |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
NCI-2014-01043 NCI-2014-01043 MC1315 9608 9608 P30CA015083 UM1CA186686 |
|||
Sponsor: |
National Cancer Institute (NCI) |
|||
Patient Contact: |
See contacts at open sites |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
This phase I trial studies the side effects and the best dose of navitoclax (BCL-2 inhibitor) when given together with sorafenib tosylate (Nexavar) in treating patients with solid tumors that have returned (relapsed) or do not respond to treatment (refractory). Navitoclax and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
New York |
NY |
10032 |
USA |
||
Rochester |
MN |
55905 |
USA |
||
Baltimore |
MD |
21201 |
USA |
||
Scottsdale |
AZ |
85259 |
USA |